WR 1065
(Synonyms: 硫代乙基氨基乙基胺盐酸盐) 目录号 : GC11557
A radioprotective agent
Cas No.:14653-77-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Kinase experiment: | For Western analysis, cells are treated with 1 mM WR-1065 dihydrochloride (WR-1065) for 24 h, and subconfluent cultures of cells are harvested and lysed in RIPA buffer supplemented with protease inhibitors. Protein concentrations are determined by a detergent-compatible assay. Western blots are blocked and incubated in antibody in PBS/0.2% Tween 20/5% nonfat dry milk. Blots are incubated with 1 μg/mL antibody for 1 h at room temperature, followed by washing in PBS/0.2% Tween 20 and incubation in peroxidase-conjugated secondary antibody and chemiluminescence detection[2]. |
Cell experiment: | To test the effects of paclitaxel in the presence or absence of WR-1065 dihydrochloride (WR-1065) on cell growth, cells are seeded in 96-well tissue culture dishes at 20% confluence and allowed to attach and recover for at least 24 h. Varying combinations of paclitaxel alone or in combination with a 60 min pretreatment with 1 mM WR-1065 dihydrochloride are then added to each well, and the plates are incubated for an additional 48 h or 72 h. The number of surviving cells is determined by staining. The percentage of cells killed by paclitaxel and/or WR-1065 dihydrochloride is calculated as the percentage decrease in sulforhodamine B binding compare with control cells[2]. |
Animal experiment: | Seventy two rats are divided randomly into 9 equal groups: 1) Control group receives no injection and is left untreated for the entire period of the experiment as intact animals; 2) Sham operated group is subjected only to surgical procedure; 3) Vehicle (saline)-treated group receives 2 μL saline (intra-SNc); 4) Lesioned group receives 6-hydroxydopamine; 5) Vehicle+6OHDA group receives saline as a vehicle 3 days once daily (2 μL/rat) before 6-OHDA injection; 6 to 8) Rats in these groups are pretreated with intra-SNc injection of WR-1065 dihydrochloride (WR-1065) (20, 40 and 80 μg/2 μL/rat) 3 days before 6-OHDA injection; 9) Non-lesioned animals receive intra-SNc injection of WR-1065 dihydrochloride (80 μg/2 μL/rat) for three days[3]. |
References: [1]. Pluquet O, et al. The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase. J Biol Chem. 2003 Apr 4;278(14):11879-87. | |
WR-1065, a dephosphorylated metabolite of amifostine?(Ethyol), can protect against the immediate and delayed effects of radiation exposure.
WR-1065 can protect against zidovudine (AZT) – induced genetoxicity. The lymphoblastoid cell line MOLT-3 cells were exposed to 0/10μM AZT for 96h. In the first 24h 0/5?μM WR-1065 was added and Cyt B was added in 76h in the cells, the viability of AZT treated MOLT-3 cells did not altered.[1] Moreover, in RKO36 cell lines (derivative RKO human colorectal carcinoma carrying a GFP-pCMV-EGFP2Xho), 4 mM final concentration (EC50) WR-1065 treatment for 30min immediately before irradiation showed protective effects against cell chromosomal damage and death induced by ionizing radiation and delayed genomic instability. But 40??M WR-1065 did not show immediate radio-protective effects in irradiated RKO36 cells.[2] WR-1065 acts as radioprotective agents mainly through suppression of the homologous recombination pathway. In SPD8 Chinese hamster cell line, both 4 mM WR-1065 for 30min and 10 ?M for 24h significantly reduced the homologous recombination induced by 0.2 mM Hydroxyurea for 24h or 100 nM camptothecin for 1h. While WR-1065 did not show its radioprotective effects in irradiated homologous recombination-deficient irs 1SF cells compared with homologous recombination-proficient cells AA8/CXR3(P＜0.05).[3]
With spray drying technique using PLGA (polylactide co-glycolide) as the polymer matrix, WR-1065 were prepared into nanoparticles. 500mg/kg WR-1065/PLGA nanoparticles in which containing 21.7(w/w WR-1065) were administrated orally in mice to determined its radio-protective role. WR-1065PLGA nanoparticles treatment mice showed noteworthy higher 30-day survival, less bone marrow suppression and less intestinal injury compared non-treated control mice, indicated its significant radio-protective effects.[4]
References:
[1]. Ofelia A . Olivero, Michael O. Ong, Han nan M. Braun, Ariadna Marrogi, Kathyiani Divi, James B. Mitchel l, and Miriam C. Poirier. Selective protection of zidovadine-induced DNA-damage by antioxidants WR-1065 and tempol. Environmental and Molecular Mutagenesis (2014)55: 566-572
[2]. Jaroslaw Dziegielewski, Janet E. Baulch, Wilfried Goetz, Mitchell C. Coleman, Douglas R. Spitz, Jeffrey S. Murley, David J. Grdina, and William F. Morgan. WR-1065, the active metabolite of amifostine, mitigates radiation-induced delayed genomic instability. Free Radic Biol Med. (2008)45(12): 1674–1681
[3]. Jaroslaw Dziegielewski, Wilfried Goetz, Jeffrey S. Murley, David J. Grdina, William F. Morgan, and Janet E. Baulch. Amifostine Metabolite WR-1065 Disrupts Homologous Recombination in Mammalian Cells. Radiat Res. (2010) 173(2): 175–183
[4]. Sarala Pamujula,?Vimal Kishore,?Barbara Rider,?Krishna C. Agrawal, and?Tarun K. Mandal. Radioprotection in mice following oral administration of WR-1065/PLGA nanoparticles. (2008) 84(11): 900-908
| Cas No. | 14653-77-1 | SDF | |
| 别名 | 硫代乙基氨基乙基胺盐酸盐 | ||
| 化学名 | 2-(3-aminopropylamino)ethanethiol;dihydrochloride | ||
| Canonical SMILES | C(CN)CNCCS.Cl.Cl | ||
| 分子式 | C5H14N2S.2HCl | 分子量 | 207.16 |
| 溶解度 | PBS (pH 7.2): 10 mg/ml | 储存条件 | Desiccate at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.8272 mL | 24.1359 mL | 48.2719 mL |
| 5 mM | 0.9654 mL | 4.8272 mL | 9.6544 mL |
| 10 mM | 0.4827 mL | 2.4136 mL | 4.8272 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。